IFITM5 抗体 (PE-Cy7)
Quick Overview for IFITM5 抗体 (PE-Cy7) (ABIN1713214)
抗原
See all IFITM5 抗体适用
宿主
克隆类型
标记
应用范围
-
-
预测反应
- Human
-
纯化方法
- Purified by Protein A.
-
免疫原
- KLH conjugated synthetic peptide derived from human IFITM5
-
亚型
- IgG
-
-
-
-
应用备注
-
FCM(1:100-500)
Optimal working dilution should be determined by the investigator. -
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- 1 μg/μL
-
缓冲液
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
-
储存条件
- -20 °C
-
储存方法
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
-
有效期
- 12 months
-
-
- IFITM5 (Interferon Induced Transmembrane Protein 5 (IFITM5))
-
别名
- IFITM5
-
背景
-
Synonyms: Bone-restricted interferon-induced transmembrane protein-like protein, BRIL, Fragilis4, Hrmp1, ITM5, M5_HUMAN, Interferon-induced transmembrane protein 5.
Background: IFITM5 is a membrane protein thought to play a role in bone mineralization. This gene is located on chromosome 11 in a cluster of related genes which are induced by interferon, however, this gene has not been shown to be interferon inducible. A similar gene, located in a gene cluster on mouse chromosome 7, is a member of the interferon-inducible fragilis gene family. The mouse gene encodes a transmembrane protein described as participating in germ cell competence. A mutation in the 5' UTR of this gene has been associated with osteogenesis imperfecta type V (PMID: 22863190, 22863195).
抗原
-